Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report ...

Additionally given a 30-day option to buy up to an extra 975,000 shares at the same price are underwriters. About $49.5 ...

Stock analysts at Leerink Partnrs dropped their Q2 2025 earnings estimates for shares of Encompass Health in a note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst W. Mayo now ...

We recently published an article titled Top 10 Health Information Services Stocks Outpacing The Market In 2025. In this ...

NeuroPace (Nasdaq:NPCE) today announced that it intends to sell common stock in an underwritten public offering worth $65 ...

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Encompass Health (EHC – Research Report), with a ...

Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...

Incorporated (NYSE: ELAN) shares have reached a 52-week low, dipping to $11.11, as the company faces a tumultuous market environment. With a market capitalization of $5.55 billion and a beta of 1.42, ...